Healthcare, Pharma, Medical Device etc.
Category
United states of America, Europe, Rest of World
Geographic Coverage
Not Available
Video URL
Not Available
Sale price (USD)
Not Available
Non-exclusive license price (USD)
Not Available
Exclusive license price (USD)
Not Available
Non-exclusive license royalty rate %
Availability
Patent family
Number of members in the patent family
Assignee(s) / Patent owner(s)
To see the additional information details please login and subscribe to a Premium account.

Survival predictor for DLBCL patients

Patent Pending Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7-8 cases per 100,000 people per year.[2][3] This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4] DLBCL is an aggressive tumour which can arise in virtually any part of the body,[5] and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with fever, weight loss, and night sweats.

GET LICENSE BROKER APPLY submit an inquiry
photo To see the additional information details please login and subscribe to a Plus or Premium account.